King Wealth Management Group Has $3.23 Million Stake in Teva Pharmaceutical Industries Ltd. $TEVA

King Wealth Management Group reduced its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 22.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 160,000 shares of the company’s stock after selling 45,000 shares during the quarter. King Wealth Management Group’s holdings in Teva Pharmaceutical Industries were worth $3,232,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. AQR Capital Management LLC increased its position in Teva Pharmaceutical Industries by 24.6% in the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock worth $368,000 after buying an additional 4,732 shares during the period. Focus Partners Wealth increased its position in Teva Pharmaceutical Industries by 4.5% during the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock worth $616,000 after acquiring an additional 1,739 shares during the period. Vanguard Personalized Indexing Management LLC raised its stake in Teva Pharmaceutical Industries by 30.2% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 35,274 shares of the company’s stock valued at $591,000 after purchasing an additional 8,192 shares during the last quarter. CWM LLC grew its position in Teva Pharmaceutical Industries by 18.1% in the 2nd quarter. CWM LLC now owns 4,995 shares of the company’s stock worth $84,000 after purchasing an additional 767 shares during the last quarter. Finally, MGO One Seven LLC bought a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter worth about $236,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

TEVA has been the topic of a number of recent research reports. Barclays lifted their target price on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. Piper Sandler boosted their price objective on Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, December 22nd. JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Scotiabank boosted their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a report on Thursday, January 29th. Finally, Truist Financial increased their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average target price of $37.11.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $34.40 on Wednesday. The firm has a market cap of $39.46 billion, a PE ratio of 28.67, a price-to-earnings-growth ratio of 1.94 and a beta of 0.70. The company’s 50-day moving average price is $32.31 and its two-hundred day moving average price is $24.81. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. The company had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. Teva Pharmaceutical Industries’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 12,300 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total value of $371,460.00. Following the completion of the transaction, the chief accounting officer directly owned 5,650 shares of the company’s stock, valued at approximately $170,630. The trade was a 68.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Roberto Mignone sold 77,400 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the sale, the director directly owned 367,600 shares in the company, valued at $11,116,224. This trade represents a 17.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 422,060 shares of company stock valued at $12,254,965. 0.49% of the stock is owned by corporate insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.